• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only


      We are proud to present our six-part Peer-to-Peer Psoriasis

      Podcast series discussing important updates and hot

      topics in psoriasis treatment and management

      Podcast Series Host

      Your host for the Peer-to-Peer Podcast series is 

      Dr Laura Savage, Consultant Dermatologist from the Leeds Centre for Dermatology, Chapel Allerton Hospital and Honorary Senior Lecturer, University of Leeds, UK


      Dr Laura Savage is a Consultant Dermatologist (Leeds Teaching Hospitals NHS Trust) with a special interest in Medical Dermatology and Honorary Senior Lecturer (Faculty of Medicine and Health, University of Leeds). She is co-lead for the complex psoriasis service and has extensive experience in utilising targeted immunomodulatory therapies.

      Dr Savage graduated from the University of Edinburgh Medical School and subsequently trained in Dermatology within the Yorkshire Deanery. Her PhD focused on investigating the imaging and laboratory responses of subclinical disease within the synovio-entheseal complex in patients with moderate to severe psoriasis treated with biologic therapy. Her research interests cross the boundaries of both dermatology and rheumatology and relate to the development of strategies to detect and manage early PsA in patients with psoriasis. Dr Savage is also an active member of the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) and co-authored their published guidelines on the detection and treatment of enthesitis. As a natural continuation from her interest in biologic therapies, Dr Savage also has a keen interest in Hidradentiis Suppurativa. Dr Savage is an elected committee member of the British Society of Medical Dermatology. She takes an active role in medical education on a national and international level.


      JULY: Episode 1

      Clinical trial spotlight - risankizumab and secukinumab head-to-head in plaque psoriasis

      AUGUST: Episode 2

      Psoriasis in the time of COVID-19: an era of virtual clinics?             

      SEPTEMBER: Episode 3

      Psoriasis in practice: BAD guideline updates                               

      OCTOBER: Episode 4

      BAD 2020: virtual congress highlights

      NOVEMBER: Episode 5

      Are all IL-23s the same?                    

      DECEMBER: Episode 6

      EADV 2020: congress highlights       


      1. SKYRIZI (risankizumab) Summary of Product Characteristics.

      UK-RISN-210510 | Date of preparation: October 2021.